ROCKVILLE, MD and ANTRIM, UNITED KINGDOM--(Marketwire - March 31, 2009) - Seegene, Inc. and Randox Laboratories today announced that they have entered into an agreement in which Randox will obtain a non-exclusive license to Seegene’s Dual Priming Oligo (DPO™) technology to develop high-throughput diagnostic screening panels capable of simultaneously detecting a wide variety of infectious pathogens that cause either respiratory or sexually transmitted diseases.
This agreement brings together two innovative technologies: Seegene’s DPO multiplex PCR technology and Randox’s Biochip Array Technology (BAT). This powerful combination facilitates highly sensitive and specific simultaneous detection of a broad range of pathogens from a single patient sample. This in turn will provide a more comprehensive and rapid clinical diagnosis of the patient, improving laboratory efficiency and ensuring timely delivery of appropriate treatments.
In a joint statement, Dr. Jong-Yoon Chun, Chief Executive Officer of Seegene, and Dr. Peter FitzGerald, Managing Director of Randox, said that, “Through this agreement, Randox will be able to complement the sensitivity and specificity of Biochip Arrays with Seegene’s multiplex DPO technology. As a result, the tests that are developed will provide clinical laboratories with a diagnostic system capable of detecting more infections with unparalleled accuracy and speed. We are excited that the products we are developing will be vital tools in the fight against the spread of debilitating infectious diseases.”
Winner of Innovation and Engineering Awards, Randox’s Biochip Array Technology (BAT) is a novel platform for the simultaneous detection of a panel of related biological markers. The panels include Protein biochips for antigen detection, such as Drugs of Abuse, DNA biochips for mutation/SNP studies and RNA expression profiling. BAT platforms range from the high-throughput, fully automated Evidence, to the medium throughput semi-automated Investigator and near-patient automated Multistat.
Seegene’s Dual Priming Oligo (DPO) is a breakthrough multiplexing PCR technology in simultaneous multi-pathogen detection by generating consistently high specificity enabling as high as 19-multiplex PCR in a single reaction. DPO also provides substantial testing accuracy and efficiency in detection of SNPs and mutations related to cancer or drug resistance.
About Seegene
Seegene, Inc. is a biotechnology company specialized in molecular diagnostics and research applications. It holds a novel detection platform named “Seeplex,” which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplexing.” Seeplex technology accurately detects multi-pathogens with high-throughput, ultimately providing the most economical basis for saving time, labour and cost. Seegene develops, manufactures and markets innovative molecular diagnostic products and services to a worldwide community. Its mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology, and chromosomal analyses using innovative proprietary technologies. For more information please visit www.seegene.com or call +1 301-762-9066.
About Randox
Randox is an international diagnostics company, headquartered in the UK. Randox develop, manufacture and market clinical diagnostic products worldwide. Our mission is to revolutionise healthcare through continuously improving diagnostic solutions. Core products include the multi-award winning Biochip Array Technology, with a growing portfolio of multi-analyte assays for clinical and research use; RX Series clinical chemistry analysers and reagents, providing easy to use, high-throughput tests for all clinical applications; quality controls and EQA, to give confidence in your results; environmental diagnostics and a comprehensive range of recombinant proteins and antibodies. For more information, please visit www.Randox.com or contact marketing@randox.com, Tel: +44 (0) 28 9442 2413.
Contacts:
Sang Kil Lee, Ph.D.
Seegene Inc.
+1 301-762-9066
Email Contact
Constantine Theodoropulos
Base Pair Communications
Constantine[at]basepaircomm.com